Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Routinely available
SMC (SMC2207)
18/12/2019
Indication
In combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available in line with national guidance
Formulation
25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion
Comments
December 2019 - Routinely available in line with national guidance. Included on the Additional List for Specialist Use only.
Link to Advice
Advice Published
07/10/2019
SMC Submission Type
Resubmission
SMC Status
Restricted